Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Therapy01:28

Drug Therapy

83
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
83
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

333
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
333
Psychosis: Goals of Pharmacotherapy01:26

Psychosis: Goals of Pharmacotherapy

185
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
185
Attention-Deficit/Hyperactivity Disorder01:30

Attention-Deficit/Hyperactivity Disorder

140
Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder characterized by persistent inattention, hyperactivity, and impulsivity. It affects approximately 5-8% of children globally, with around 60-70% of cases persisting into adulthood. ADHD has significant implications for educational attainment, social interactions, and occupational success.
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings....
140
Antipsychotic Drugs: Typical and Atypical Agents01:21

Antipsychotic Drugs: Typical and Atypical Agents

286
Antipsychotic drugs are classified into first-generation (typical) drugs including phenothiazines; and second-generation (atypical) drugs. Chlorpromazine hydrochloride (Thorazine), a phenothiazine derivative, broadly impacts the central, autonomic, and endocrine systems. This drug, along with typical agents like haloperidol (Haldol), primarily works by antagonizing D2 receptors, thus reducing dopaminergic neurotransmission. However, typical antipsychotics can cause side effects such as sedation...
286

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Trio analysis in dystonia identifies de novo KLC1 variants in a kinesinopathy with distinct motor and neurodevelopmental features.

EBioMedicine·2026
Same author

Multiecho Resting-State Functional Magnetic Resonance Imaging Analysis of Attention-Deficit/Hyperactivity Disorder Severity and Motor Dysfunction in a Pediatric Sample of Neurofibromatosis Type 1.

Pediatric neurology·2026
Same author

Treatment non-persistence in children and adolescents with Tourette syndrome newly treated with dopamine D2 receptor modulators.

Frontiers in psychiatry·2026
Same author

Education Research: The Future of Child Neurology Residency Training: The Perspective of a Child Neurology Society Task Force.

Neurology. Education·2026
Same author

Shortened Cortical Silent Period in Children with Attention Deficit Hyperactivity Disorder.

medRxiv : the preprint server for health sciences·2026
Same author

Developmental delay in attaining adult levels of motor excitability in children and adolescents with Tourette syndrome: a mega-analysis study.

bioRxiv : the preprint server for biology·2026

Related Experiment Video

Updated: Aug 14, 2025

Event Related Potentials ERPs and other EEG Based Methods for Extracting Biomarkers of Brain Dysfunction: Examples from Pediatric Attention Deficit/Hyperactivity Disorder ADHD
10:02

Event Related Potentials ERPs and other EEG Based Methods for Extracting Biomarkers of Brain Dysfunction: Examples from Pediatric Attention Deficit/Hyperactivity Disorder ADHD

Published on: March 12, 2020

15.8K

Ecopipam for Tourette Syndrome: A Randomized Trial.

Donald L Gilbert1,2, Jordan S Dubow3, Timothy M Cunniff4

  • 1Division of Neurology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio.

Pediatrics
|January 11, 2023
PubMed
Summary

Ecopipam significantly reduced tics in children and adolescents with Tourette syndrome compared to placebo. This novel dopamine 1 receptor antagonist demonstrated efficacy without the common side effects associated with antipsychotics.

More Related Videos

Handwriting Analysis Indicates Spontaneous Dyskinesias in Neuroleptic Naïve Adolescents at High Risk for Psychosis
05:52

Handwriting Analysis Indicates Spontaneous Dyskinesias in Neuroleptic Naïve Adolescents at High Risk for Psychosis

Published on: November 21, 2013

15.0K
Signal Attenuation as a Rat Model of Obsessive Compulsive Disorder
09:29

Signal Attenuation as a Rat Model of Obsessive Compulsive Disorder

Published on: January 9, 2015

15.5K

Related Experiment Videos

Last Updated: Aug 14, 2025

Event Related Potentials ERPs and other EEG Based Methods for Extracting Biomarkers of Brain Dysfunction: Examples from Pediatric Attention Deficit/Hyperactivity Disorder ADHD
10:02

Event Related Potentials ERPs and other EEG Based Methods for Extracting Biomarkers of Brain Dysfunction: Examples from Pediatric Attention Deficit/Hyperactivity Disorder ADHD

Published on: March 12, 2020

15.8K
Handwriting Analysis Indicates Spontaneous Dyskinesias in Neuroleptic Naïve Adolescents at High Risk for Psychosis
05:52

Handwriting Analysis Indicates Spontaneous Dyskinesias in Neuroleptic Naïve Adolescents at High Risk for Psychosis

Published on: November 21, 2013

15.0K
Signal Attenuation as a Rat Model of Obsessive Compulsive Disorder
09:29

Signal Attenuation as a Rat Model of Obsessive Compulsive Disorder

Published on: January 9, 2015

15.5K

Area of Science:

  • Neuroscience
  • Pharmacology
  • Clinical Trials

Background:

  • Current Tourette syndrome (TS) treatments, primarily antipsychotics, carry risks of weight gain, metabolic changes, and movement disorders.
  • Ecopipam, a selective dopamine 1 receptor antagonist, has shown promise in small trials for tic reduction with a potentially better safety profile.
  • This study aimed to further assess ecopipam's efficacy and safety in pediatric TS patients.

Purpose of the Study:

  • To evaluate the efficacy of ecopipam in reducing tics in children and adolescents with moderate to severe Tourette syndrome.
  • To assess the safety and tolerability of ecopipam compared to placebo.
  • To compare the adverse event profiles between ecopipam and placebo groups.

Main Methods:

  • A multicenter, randomized, double-blind, placebo-controlled, phase 2b trial.
  • Inclusion of subjects aged 6 to 17 years with moderate to severe Tourette syndrome (Yale Global Tic Severity Score ≥20).
  • Random assignment to ecopipam or placebo for 12 weeks, with primary endpoint as change in Yale Global Tic Severity Score.

Main Results:

  • Ecopipam demonstrated a statistically significant reduction in total tic scores compared to placebo over 12 weeks (P = .01).
  • Greater improvement was observed in the Clinical Global Impression of Tourette Syndrome Severity in the ecopipam group (P = .03).
  • Weight gain was more prevalent in the placebo group; no significant metabolic or ECG changes were noted. Common adverse events included headache, insomnia, fatigue, and somnolence.

Conclusions:

  • Ecopipam effectively reduces tics in pediatric patients with Tourette syndrome.
  • The drug shows a favorable safety profile, lacking common antipsychotic-associated side effects.
  • Ecopipam represents a promising alternative treatment for Tourette syndrome in children and adolescents.